Abeona Therapeutics Inc (NASDAQ:ABEO) Expected to Post Q1 2024 Earnings of ($0.47) Per Share

Abeona Therapeutics Inc (NASDAQ:ABEO) – Research analysts at Zacks Small Cap issued their Q1 2024 earnings estimates for shares of Abeona Therapeutics in a research note issued to investors on Thursday, April 25th. Zacks Small Cap analyst D. Bautz expects that the biopharmaceutical company will post earnings per share of ($0.47) for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($2.05) per share.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13).

ABEO has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, April 23rd. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd.

Abeona Therapeutics Stock Performance

Shares of NASDAQ:ABEO opened at $4.14 on Monday. The firm has a market cap of $113.23 million, a PE ratio of -1.60 and a beta of 1.49. The firm’s 50 day simple moving average is $7.16 and its 200-day simple moving average is $5.62. Abeona Therapeutics has a one year low of $2.83 and a one year high of $9.01.

Insider Buying and Selling at Abeona Therapeutics

In other news, SVP Brendan M. O’malley bought 8,600 shares of the stock in a transaction on Thursday, April 25th. The stock was bought at an average cost of $3.24 per share, for a total transaction of $27,864.00. Following the completion of the purchase, the senior vice president now directly owns 188,718 shares in the company, valued at $611,446.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Vishwas Seshadri acquired 10,000 shares of the stock in a transaction dated Thursday, April 25th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $32,000.00. Following the completion of the purchase, the chief executive officer now owns 538,260 shares of the company’s stock, valued at approximately $1,722,432. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Brendan M. O’malley acquired 8,600 shares of the stock in a transaction dated Thursday, April 25th. The shares were bought at an average price of $3.24 per share, with a total value of $27,864.00. Following the completion of the purchase, the senior vice president now directly owns 188,718 shares of the company’s stock, valued at approximately $611,446.32. The disclosure for this purchase can be found here. Insiders bought a total of 31,758 shares of company stock worth $102,237 over the last three months. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Simplex Trading LLC lifted its position in Abeona Therapeutics by 1,889.9% during the third quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 13,418 shares during the period. Jump Financial LLC acquired a new position in Abeona Therapeutics during the fourth quarter valued at $199,000. Schonfeld Strategic Advisors LLC acquired a new position in Abeona Therapeutics during the third quarter valued at $648,000. Worth Venture Partners LLC lifted its position in Abeona Therapeutics by 76.6% during the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 121,969 shares during the period. Finally, Barclays PLC lifted its position in Abeona Therapeutics by 100.0% during the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after purchasing an additional 185,638 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.